{"log_id": 5970210581408680512, "direction": 0, "words_result_num": 34, "words_result": [{"probability": {"variance": 0.034136, "average": 0.868863, "min": 0.366332}, "location": {"width": 1106, "top": 292, "height": 43, "left": 322}, "words": "宫马酸诺韦二吡呋:一项在初次接受治疗的成人受试中开展的为期144周的试验表明"}, {"probability": {"variance": 0.032076, "average": 0.895868, "min": 0.37941}, "location": {"width": 1150, "top": 331, "height": 36, "left": 276}, "words": "内组思者的腰和部的肯矿物质密度(EMD)下降。在第141周,与接受司他大定+拉米大定"}, {"probability": {"variance": 0.012336, "average": 0.939793, "min": 0.49603}, "location": {"width": 1168, "top": 363, "height": 43, "left": 269}, "words": "依法韦伦的受试者相比,接受富马酸替诺福韦二吡1拉米大定十依法事伦治疗的受试者腰椎骨矿"}, {"probability": {"variance": 0.011697, "average": 0.945409, "min": 0.554677}, "location": {"width": 1170, "top": 397, "height": 43, "left": 267}, "words": "物质密度相对于基线值的下降平均百分比听显较高。这两个治疗组中就部骨矿物质密度的变化相似"}, {"probability": {"variance": 0.003311, "average": 0.973207, "min": 0.689025}, "location": {"width": 1163, "top": 434, "height": 43, "left": 265}, "words": "两个治疗组中,骨矿物质密度的下降大部分发生在试验的前24~48周,直至第144,下降保持"}, {"probability": {"variance": 0.01556, "average": 0.931027, "min": 0.434721}, "location": {"width": 1156, "top": 468, "height": 43, "left": 267}, "words": "稳定,接受马酸诺福二吡呋酯治疗的受试者中有28%,对照组中有21%的受试者腰椎的矿"}, {"probability": {"variance": 0.024456, "average": 0.920834, "min": 0.387886}, "location": {"width": 1163, "top": 502, "height": 43, "left": 262}, "words": "物质密度丢失至少为5%或部的骨矿物质密度丢失至少为7,宫马酸替诺福韦二吡呋酯组有4"}, {"probability": {"variance": 0.016228, "average": 0.918569, "min": 0.512411}, "location": {"width": 1175, "top": 537, "height": 45, "left": 262}, "words": "名受试者,对照组中有6名受试者报告了临床上相关的骨折(手指和脚趾除外):富马酸替诺福市"}, {"probability": {"variance": 0.017744, "average": 0.918502, "min": 0.416127}, "location": {"width": 1140, "top": 576, "height": 41, "left": 292}, "words": "吡南组中骨气谢的生化记物(血清骨特异性碱性磷酸酶、血清骨钙素、血清基端肽、尿如"}, {"probability": {"variance": 0.029818, "average": 0.895037, "min": 0.374957}, "location": {"width": 1175, "top": 610, "height": 43, "left": 260}, "words": "基端肽)显著升高,提示骨转化增加。马酸裤诺福当二吐酯组中受试者的血清甲状腺激素水"}, {"probability": {"variance": 0.003173, "average": 0.96749, "min": 0.834225}, "location": {"width": 370, "top": 647, "height": 34, "left": 260}, "words": "平和1,25维生素水平也较高"}, {"probability": {"variance": 0.008218, "average": 0.954876, "min": 0.597324}, "location": {"width": 1120, "top": 711, "height": 45, "left": 313}, "words": "在一项对12岁(含)以上感染HV-1的儿童受试者进行的临床试验(321号研究)中,骨影响"}, {"probability": {"variance": 0.024887, "average": 0.911068, "min": 0.42718}, "location": {"width": 1172, "top": 747, "height": 48, "left": 258}, "words": "和成人受试者相似。在正常情况下,该年龄段中,B迅速增而在本试验中,富马酸替港福韦"}, {"probability": {"variance": 0.021689, "average": 0.928274, "min": 0.3711}, "location": {"width": 1150, "top": 784, "height": 43, "left": 285}, "words": "呋酯治疗组的骨增量平均速率低于安慰剂。在48周内,富马酸替诺梅书二比酯治疗组的G"}, {"probability": {"variance": 0.026076, "average": 0.910711, "min": 0.461953}, "location": {"width": 1168, "top": 820, "height": 41, "left": 258}, "words": "名受试者安慰剂治疗组的1名受试者在其腰椎处出D明显丢失(大于4%,在接受96周宫"}, {"probability": {"variance": 0.017274, "average": 0.932032, "min": 0.433646}, "location": {"width": 1159, "top": 855, "height": 43, "left": 253}, "words": "马酸替诺福韦二呋治疗的28名受试者中,其腰椎和全身的Z一分值分别下降了-0.341和-0.458"}, {"probability": {"variance": 0.013044, "average": 0.939063, "min": 0.542722}, "location": {"width": 1170, "top": 891, "height": 43, "left": 251}, "words": "骨骼生长高度)似乎未受影响。在富马酸替诺福韦二壮呋酯治疗的12岁(含)以上的儿童受试"}, {"probability": {"variance": 0.000735, "average": 0.98554, "min": 0.882241}, "location": {"width": 930, "top": 925, "height": 43, "left": 253}, "words": "者中,骨转化标记物表明,骨转化增加,这和在成人中观察到的效果相一致"}, {"probability": {"variance": 0.018819, "average": 0.938383, "min": 0.391732}, "location": {"width": 1095, "top": 992, "height": 45, "left": 308}, "words": "富马酸替诺韦二吡呋酯相关的骨矿物质密度和生化标记物变化对长期骨健康和未来骨折风"}, {"probability": {"variance": 0.027808, "average": 0.90814, "min": 0.359748}, "location": {"width": 985, "top": 1028, "height": 43, "left": 251}, "words": "险的影响仍然未明确:要获取额外信息,请参阅富马酸替诺福二吡处方信息"}, {"probability": {"variance": 0.009005, "average": 0.960174, "min": 0.456126}, "location": {"width": 1118, "top": 1092, "height": 48, "left": 306}, "words": "曾经报道过与使用高马酸替诺福十二吡呋酯有关的骨软化症(与近端肾小管病变有关,并可能"}, {"probability": {"variance": 0.025919, "average": 0.908981, "min": 0.351422}, "location": {"width": 468, "top": 1129, "height": 34, "left": 253}, "words": "导致骨折)病(参见【不良反应】)"}, {"probability": {"variance": 0.001411, "average": 0.969476, "min": 0.912534}, "location": {"width": 166, "top": 1198, "height": 32, "left": 249}, "words": "脂肪重新分布"}, {"probability": {"variance": 0.009082, "average": 0.951324, "min": 0.599227}, "location": {"width": 1108, "top": 1262, "height": 48, "left": 304}, "words": "接受抗逆转录病毒治疗的患中,曾经观察到体脂重新分布/堆积包括向心性肥胖、项背肪"}, {"probability": {"variance": 0.025423, "average": 0.908995, "min": 0.353873}, "location": {"width": 1172, "top": 1298, "height": 45, "left": 246}, "words": "增加(水背)、周围消瘦、面部清瘦、胸部增大和柯兴氏面容,这些现象发生的机制和长期后"}, {"probability": {"variance": 0.04159, "average": 0.853371, "min": 0.44787}, "location": {"width": 409, "top": 1335, "height": 34, "left": 249}, "words": "果目前末明确。因果关系尚未确立"}, {"probability": {"variance": 0.037578, "average": 0.802052, "min": 0.469215}, "location": {"width": 201, "top": 1401, "height": 43, "left": 242}, "words": "免疫重建结合征"}, {"probability": {"variance": 0, "average": 0.813555, "min": 0.813555}, "location": {"width": 22, "top": 1442, "height": 25, "left": 436}, "words": "9"}, {"probability": {"variance": 0.009417, "average": 0.950461, "min": 0.482273}, "location": {"width": 1115, "top": 1465, "height": 50, "left": 299}, "words": "接受包括恩江背诺福韦在内抗逆转录病毒联合治疗的患者中,曾经报告过免疫重建综合征"}, {"probability": {"variance": 0.02397, "average": 0.923156, "min": 0.376601}, "location": {"width": 1163, "top": 1502, "height": 48, "left": 249}, "words": "在抗逆转录病毒联1疗的初期,免疫系统应答的患者有可能对顽固性或残余的机会性感染(例如"}, {"probability": {"variance": 0.016118, "average": 0.930249, "min": 0.494331}, "location": {"width": 1161, "top": 1536, "height": 50, "left": 244}, "words": "鸟核分枝杆菌感、细胞病、肺孢子菌肺炎(FCP)或结核)产生炎症性应答,对此有必要"}, {"probability": {"variance": 0.065815, "average": 0.792008, "min": 0.359031}, "location": {"width": 240, "top": 1572, "height": 34, "left": 249}, "words": "再步评价和治疗"}, {"probability": {"variance": 0.025472, "average": 0.888475, "min": 0.382962}, "location": {"width": 1120, "top": 1634, "height": 57, "left": 290}, "words": "武外有在建的过程中发生自免疫失清(例如格夫斯病,多肌炎和格林一巴利综"}, {"probability": {"variance": 0.028827, "average": 0.8997, "min": 0.363483}, "location": {"width": 962, "top": 1673, "height": 50, "left": 237}, "words": "合征义的0,发病的时间更多样化,也可能在开始治疗后数个月内发生"}], "language": 3}